01 / OVERVIEW
One molecule, three receptor targets.
Retatrutide is an experimental medicine developed by Lilly. It activates GIP, GLP-1 and glucagon receptors. The term “triple agonist” describes these three targets; “GLP-3” is not its scientific classification. [1]
02 / RESEARCH AIMS
Why researchers are investigating it.
Studies examine obesity and type 2 diabetes, alongside related conditions such as obstructive sleep apnea and knee osteoarthritis pain. These are research questions, rather than established uses for a consumer product. [1]
03 / MECHANISM
What “activating a receptor” means.
A receptor is a molecular target that responds to a signal. An agonist activates that target. Retatrutide combines activity at three receptors in a single molecule; this mechanism is the basis for investigating its metabolic effects. Receptor activity alone does not establish a clinical benefit. [2]
04 / OBSERVED EFFECTS
What human research has shown.
A randomized phase 2 trial in adults with obesity reported substantial average reductions in body weight over 48 weeks. Results describe the trial population and study medicine, not a guaranteed individual outcome. [2]
Lilly has also announced phase 3 results. Its July 2026 overview distinguishes topline announcements from detailed results awaiting presentation and publication. A company announcement and a peer-reviewed paper offer different levels of detail for scrutiny. [1]
Human trials
Measure outcomes in people under defined study conditions.
Preclinical studies
Explore mechanisms in laboratory and animal models; they cannot alone establish human efficacy or safety.
Open questions
Findings still need to be interpreted alongside limitations and unanswered safety questions.
This short guide focuses on clinical evidence; it is not a systematic review.
05 / SAFETY AND LIMITATIONS
Effects include adverse effects.
Gastrointestinal adverse events were common in the phase 2 study. Researchers also observed increases in heart rate. Long-term outcomes require further evaluation. [2]
A clinical trial does not verify the identity, purity, sterility or effects of an independently supplied vial.
06 / REFERENCES
Go to the source.
- Lilly: What to know about retatrutide ↗
Developer overview, updated July 2026. Used for development status and research scope; the developer has a commercial interest.
- Jastreboff et al. — Retatrutide for obesity, phase 2 trial ↗
New England Journal of Medicine, 2023. Peer-reviewed, randomized clinical trial; funded by Lilly. PubMed record links to the publication.